ORIGINAL RESEARCH article
Front. Genet.
Sec. RNA
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1648077
ST8SIA6-AS1 serves as a prognostic biomarker in cancer and exhibits oncogenic properties in prostate cancer
Provisionally accepted
- 1Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China
- 2Department of Urology, The Second Hospital of Longyan, Longyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: The prognostic significance of long non-coding RNA ST8SIA6-AS1 remains ambiguous, and its biological role in prostate cancer (PCa) has not been thoroughly investigated. This study seeks to conduct a comprehensive meta-analysis to assess the clinical relevance of ST8SIA6-AS1 across different malignancies, with a particular emphasis on elucidating its functions in the advancement of PCa. Methods: Systematic searches were conducted in the PubMed, Embase, and Web of Science databases to select studies that met the criteria. Data, including hazard ratios (HR) with 95% confidence intervals (95% CI) and clinical pathological parameters, were collected. Subgroup analyses were performed based on sample size and tumor type. The expression profile analysis of PCa tissues was performed using the GTEx and TCGA databases. Changes in cell phenotype were assessed through Transwell migration assays and EdU proliferation assays. Additionally, the biological effects of ST8SIA6-AS1 were validated using an in vivo xenograft tumor model. Results: The meta-analysis including 11 studies with a total of 2,392 patients showed that high expression levels of ST8SIA6-AS1 are significantly positively correlated with reduced overall survival in patients with malignant tumors (HR=1.48, 95% CI: 1.31-1.65), increased tumor size (OR=2.07, 95% CI: 1.35-3.18), and advanced TNM staging (OR=2.83, 95% CI: 1.77-4.52). Experimental findings confirmed that ST8SIA6-AS1 expression is significantly upregulated in PCa tissues and cells. Furthermore, the knockdown of ST8SIA6-AS1 inhibited cell migration, invasion, and proliferation in vitro, as well as suppresses cell growth in vivo. Conclusion: ST8SIA6-AS1, a significant oncogenic lncRNA, could promote disease progression in PCa and could serve as a significant prognostic marker for adverse outcomes in cancer.
Keywords: ST8SIA6-AS11, Prostate Cancer2, prognosis3, meta-analysis4, biomarker5
Received: 16 Jun 2025; Accepted: 20 Oct 2025.
Copyright: © 2025 Wen, Yang, Zhan, Huang, Chen, Zheng and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shaoxing Zhu, zsxing2005@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.